GDAS Reduces Blood-Borne Virus Diagnosis Times

GDAS Transforms Blood-Borne Virus Testing in Wales

In 2024, GDAS introduced CEPHEID Blood-Borne Virus testing, reducing diagnosis times from weeks to just one day. This innovative approach is accelerating our micro-elimination efforts, ensuring faster treatment and improved public health outcomes.

Micro-Elimination: Micro-elimination refers to the targeted reduction of a specific disease to zero incidence within a defined population or geographic area. This strategy involves tailored interventions and continuous efforts to maintain elimination status.

Blood-Borne Virus Testing Machines: Blood-borne virus testing machines are specialized devices used to detect and analyze viruses transmitted through blood, such as HIV, hepatitis B, and hepatitis C. These machines process blood samples—often using dried blood spot (DBS) methods—by analyzing genetic material or antibodies to identify infections. DBS testing is a simple, non-invasive technique that involves collecting blood on filter paper, which can be easily transported and analyzed.

By integrating advanced testing technologies and focusing on micro-elimination strategies, we are making significant strides in enhancing public health and providing timely care to those affected by blood-borne viruses.

Watch how GDAS is making a difference: Watch the video here.